Sigma-Aldrich® and AB SCIEX Sign Worldwide Distribution Agreement for Mass Spectrometry Consumables

ST. LOUIS, Sept. 6, 2012 /PRNewswire/ --Sigma-Aldrich Corporation (Nasdaq: SIAL) today signed an OEM agreement with AB SCIEX, a leading company for high end mass spectrometry instruments, to globally distribute its mass spectrometry based tagging chemistries called SCIEX iChemistry^TM Solutions for applications in basic research and applied markets. The agreement strengthens the existing Sigma-Aldrich portfolio of reagents for mass spectrometry-based protein research, providing scientists access to the largest selection of high-quality tools for workflows to enable the study of the proteome. Information on the portfolio can be found at www.sigma.com/mstools.

"Mass spectrometry is a rapidly growing platform driving basic proteomics research, biomarker discovery and drug development. Particularly in the Asia-Pacific region, this distribution agreement will provide the research community with easy and reliable access to AB SCIEX's unique reagents and consumables for mass spectrometry applications as part of a total chemistry solution. Furthermore, researchers can benefit from the combined technical expertise of Sigma-Aldrich and AB SCIEX," said Josef Zihlmann, VP Marketing, Sigma-Aldrich.

The collaboration also provides a basis for future joint development of mass spectrometry consumables.

"Sigma-Aldrich is actively expanding its portfolio of robust tools for proteomics research. In addition to establishing a complete toolset for mass spectrometry research with AB SCIEX, we are continually adding to our collection of 60,000 antibodies that enable researchers to accurately discern dynamic states of proteins in key pathways throughout the proteome," said Zihlmann.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "largest," "easy," "reliable," "strengthens", "will provide", or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that tools for proteomic studies or related services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with tools for proteomic studies or  related services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

Sigma-Aldrich is a trademark of Sigma-Aldrich Co, LLC registered in the US and other countries.
iChemistry is a trademark of AB SCIEX LLC.

SOURCE Sigma-Aldrich Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED